Skip to main content

In Brief This Week: Nanosphere; Oxford BioDynamics, Janssen; Horizon Discovery; Eagle; Gentris

NEW YORK (GenomeWeb News) – Nanosphere this week received the CE IVD Mark for its Gram-Negative Blood Culture test that runs on the firm's Verigene molecular diagnostics platform. The Verigene BC-GN test provides rapid genus and species level detection for a broad panel of clinically significant gram-negative bacteria, said Nanosphere. It also detects critical genetic markers of antimicrobial resistance including KPC, NDM, CTX-M, OXA, VIM, and IMP.

Oxford BioDynamics said this week that it has signed an agreement to collaborate with Janssen Research & Development on developing epigenetic cancer biomarkers for circulating tumor cells. The firms will use Oxford's EpiSwitch platform for non-invasive detection of CTCs for diagnostic and prognostic stratification of prostate cancer patients.

Horizon Discovery has established two new centers of excellence for gene editing in Cambridge, UK. The new centers are at the Gurdon Institute, Cambridge University with Professor Steve Jackson, and the Cambridge Institute for Medical Research with Professor David Rubinsztein. Last week the firm announced it had established three new Centers of Excellence for gene editing in Asia.

UK bioinformatics firm Eagle announced that it has received ISO27001 certification, a standard of requirements and best practices for a systematic approach to managing company and customer information. The firm provides genomic analysis and data management services and helps customers move their existing bioinformatics systems to the cloud.

Gentris said this week that its Integrated Biorepository has been accredited by the College of American Pathologists. CAP established the biorepository accreditation program in 2011 to "help ensure consistent, industry-wide verification of biospecimen quality," said Gentris.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.